Organogenesis Holdings (ORGO) Non-Current Assets (2015 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Non-Current Assets of $251.5 million for Q1 2026, up 26.23% year-over-year from $199.2 million in Q1 2025, and up 6.32% quarter-over-quarter from $236.5 million in Q4 2025.
Organogenesis Holdings (ORGO) Non-Current Assets (2015 - 2026) Analysis & Trends
Organogenesis Holdings' Non-Current Assets history runs 12 years deep, the most recent figure standing at $251.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 26.23% year-over-year to $251.5 million; the TTM figure through Mar 2026 stood at $899.0 million (up 8.59% YoY), while the FY2025 annual figure was $236.5 million, up 11.61% from the prior year.
- Non-Current Assets for Q1 2026 stood at $251.5 million, up from $236.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $251.5 million in Q1 2026, with the low at $199.2 million in Q1 2025.
- The 5-year median for Non-Current Assets is $226.7 million (2022), against an average of $223.0 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 63.07% in 2022, then slipped 13.87% in 2025.
- Organogenesis Holdings' Non-Current Assets stood at $226.8 million in 2022, then advanced by 3.63% to $235.0 million in 2023, then declined by 9.8% to $211.9 million in 2024, then grew by 11.61% to $236.5 million in 2025, then climbed by 6.32% to $251.5 million in 2026.
- Business Quant data shows ORGO's Non-Current Assets at $251.5 million in Q1 2026, $236.5 million in Q4 2025, and $210.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 2.96 Bn |
| 10 | Organogenesis Holdings | 240.62 Mn | 193.78 Mn | 20.08 Mn | 206.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 206.14 Mn |
| Mar 31, 2026 | 251.49 Mn |
| Dec 31, 2025 | 236.54 Mn |
| Sep 30, 2025 | 210.08 Mn |
| Jun 30, 2025 | 200.91 Mn |
| Mar 31, 2025 | 199.23 Mn |
| Dec 31, 2024 | 211.95 Mn |
| Sep 30, 2024 | 207.79 Mn |
| Jun 30, 2024 | 208.97 Mn |
| Mar 31, 2024 | 231.31 Mn |
| Dec 31, 2023 | 234.98 Mn |
| Sep 30, 2023 | 237.07 Mn |
| Jun 30, 2023 | 233.88 Mn |
| Mar 31, 2023 | 229.29 Mn |
| Dec 31, 2022 | 226.75 Mn |
| Sep 30, 2022 | 226.75 Mn |
| Jun 30, 2022 | 224.81 Mn |
| Mar 31, 2022 | 218.42 Mn |
| Dec 31, 2021 | 216.28 Mn |
| Sep 30, 2021 | 158.59 Mn |